

**Company name: MRI2CT Website: [www.mri2ct.ai](http://www.mri2ct.ai)**

**CEO name: Shmulik Shpiro**

**Select a CATEGORY: Medical Devices**

**Select one SESSION per abstract from the list below \***

**"Beyond Bones and Screws: Rethinking Orthopedic repair"**

**Executive Summary / Investment Rational:**

MRI2CT is transforming spine surgery by converting standard MRI into high resolution synthetic CT in under 30 seconds, eliminating CT dependency. Targets spine and ASC workflows, reducing radiation, cost, and delays. With initial revenues and a collaboration with a leading spine player, the company is redefining workflows, backed by strategic and physician investors and an experienced medtech team.

**Core Technology:**

AI based platform transforming routine MRI into CT equivalent images with high geometric accuracy. Works without special MRI sequences. Enables precise and auto measurements, segmentation, registration and integration with navigation and robotics within a standard MRI only workflow. Differentiated by speed, accuracy, and MRI only workflow, removing CT dependency while maintaining surgical grade quality.

**Product Profile/Pipeline:**

Flagship platform delivers synthetic CT, segmentation, and 2D3D registration for spine surgery planning and navigation. FDA pending for lumbar spine. Expanding to full spine, age 12 plus and additional orthopedic indications. Active collaborations with strategic partners for integration into navigation and robotic platforms. Strong market potential across hospitals and ASCs.

**Business Strategy:**

Commercialize via software licensing and integration with navigation and robotic platforms. Near term revenue from pilots, strategic partnerships, and licensing. Long term growth through broad OEM integrations, expansion to multiple indications, and scaling in ASC settings. Focus on creating a new MRI only standard of care in musculoskeletal imaging and surgical planning.

**What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans:**

Complete FDA clearance for lumbar spine and initiate full spine, 12+ submission. Expand validation studies and clinical adoption with key sites and KOLs. Advance integrations with strategic partners. Raise additional capital to support commercialization and expansion into new indications.